How many acquisitions has Recursion Pharmaceuticals made so far?

Recursion Pharmaceuticals has completed 4 acquisitions so far, with an average acquisition amount of $258M.

Which countries does Recursion Pharmaceuticals usually acquire in?

Recursion Pharmaceuticals has made acquisitions in 3 countries with the most activity in Canada and United Kingdom.

Which sectors does Recursion Pharmaceuticals target for acquisitions?

Most of Recursion Pharmaceuticals's acquisitions are in Life Sciences Tech (4) and Artificial Intelligence (2).

In which year did Recursion Pharmaceuticals make the most acquisitions?

Recursion Pharmaceuticals was most active in 2023, with 2 acquisitions completed in that year.

List of 4 Acquisitions by Recursion Pharmaceuticals (Nov 2026)

Q: Which is Recursion Pharmaceuticals' latest acquisition?

Recursion Pharmaceuticals's most recent acquisition is Exscientia, a Developer of artificial intelligence platforms for identifying potential drug candidates, acquired in August 2024.

Recursion Pharmaceuticals has made a total of 4 acquisitions. These 4 acquisitions spanned 3 sectors—Life Sciences Tech, Artificial Intelligence, and Generative AI—across Canada, United Kingdom, and United States. Peak activity occurred in 2023 with 2 acquisitions, followed by 1 in 2020 and 1 in 2024. The average number of acquisitions per year from 2020 to 2025 is 0.6, with 0 acquisitions completed in the current calendar year. The most recent acquisition is Exscientia, which was acquired in August 2024. Founded in 2012 and based in Oxford, the company develops artificial intelligence platforms to identify potential drug candidates.

Here's the year on year acquisition history of Recursion Pharmaceuticals:

Number of Total Acquisitions

Year	# Acquisitions
2024	1
2023	2
2020	1

View all Acquisitions by Recursion Pharmaceuticals

Recent acquisitions by Recursion Pharmaceuticals

Recursion Pharmaceuticals's most recent acquisition - Exscientia is a Developer of artificial intelligence platforms for identifying potential drug candidates, founded in 2012 and located in Oxford. Recursion Pharmaceuticals acquired it in August 2024 for a price of $*****.

Here is the list of all acquisitions by Recursion Pharmaceuticals sorted by the latest acquisition date:

Acquired on	Acquired Company	Acquisition Price	Facilitators	Stake Acquired	Acquisition Multiple
Aug 08, 2024	Exscientia	erfr	ciil	22	573
May 08, 2023	Valence Labs	urog	irvg	52	673
May 08, 2023	Cyclica	evjd	ievo	83	439

View the full list of acquisitions

Media has covered Recursion Pharmaceuticals for a total of 21 events in the last 1 year, 4 of them have been about acquisition activity.

•

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their CollaborationFinancial Post•Oct 15, 2026•Recursion Pharmaceuticals, Sanofi

•

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery ProgramStock Screener•Aug 05, 2026•Recursion Pharmaceuticals, Genentech

•

Recursion Pharmaceuticals Director Sells $158,500 Worth of StockInvesting•Jul 10, 2026•Recursion Pharmaceuticals

•

Recursion Expands Strategic Partnership with CitelineGlobeNewswire•Mar 31, 2026•Recursion Pharmaceuticals, Citeline

View More Recursion Pharmaceuticals Recent News

View all Acquisitions by Recursion Pharmaceuticals

Acquisitions by Recursion Pharmaceuticals

List of Recursion Pharmaceuticals's Acquisitions

Recent acquisitions by Recursion Pharmaceuticals

News related to Recursion Pharmaceuticals's acquisitions

FAQs about Acquisitions by Recursion Pharmaceuticals